Inducible de novo expression of neoantigens in tumor cells and mice.


Journal

Nature biotechnology
ISSN: 1546-1696
Titre abrégé: Nat Biotechnol
Pays: United States
ID NLM: 9604648

Informations de publication

Date de publication:
01 2021
Historique:
received: 02 12 2019
accepted: 23 06 2020
revised: 13 06 2020
pubmed: 29 7 2020
medline: 12 2 2021
entrez: 29 7 2020
Statut: ppublish

Résumé

Inducible expression of neoantigens in mice would enable the study of endogenous antigen-specific naïve T cell responses in disease and infection, but has been difficult to generate because leaky antigen expression in the thymus results in central T cell tolerance. Here we develop inversion-induced joined neoantigen (NINJA), using RNA splicing, DNA recombination and three levels of regulation to prevent leakiness and allow tight control over neoantigen expression. We apply NINJA to create tumor cell lines with inducible neoantigen expression, which could be used to study antitumor immunity. We also show that the genetic regulation in NINJA mice bypasses central and peripheral tolerance mechanisms and allows for robust endogenous CD8 and CD4 T cell responses on neoantigen induction in peripheral tissues. NINJA will enable studies of how T cells respond to defined neoantigens in the context of peripheral tolerance, transplantation, autoimmune diseases and cancer.

Identifiants

pubmed: 32719479
doi: 10.1038/s41587-020-0613-1
pii: 10.1038/s41587-020-0613-1
pmc: PMC7854852
mid: NIHMS1606636
doi:

Substances chimiques

Antigens, Neoplasm 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

64-73

Subventions

Organisme : NIAID NIH HHS
ID : T32 AI007019
Pays : United States
Organisme : NCI NIH HHS
ID : K22 CA200912
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA237037
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK045735
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007974
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016359
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK034989
Pays : United States

Références

Curtsinger, J. M., Lins, D. C. & Mescher, M. F. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. 197, 1141–1151 (2003).
pubmed: 12732656 pmcid: 2193970 doi: 10.1084/jem.20021910
Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H. & Allison, J. P. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356, 607–609 (1992).
pubmed: 1313950 doi: 10.1038/356607a0
Hugues, S. et al. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat. Immunol. 5, 1235–1242 (2004).
pubmed: 15516925 doi: 10.1038/ni1134
Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987–995 (2004).
pubmed: 15454922 doi: 10.1038/ni1112
Joshi, N. S. et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27, 281–295 (2007).
pubmed: 17723218 pmcid: 2034442 doi: 10.1016/j.immuni.2007.07.010
Cebula, M. et al. An inducible transgenic mouse model for immune mediated hepatitis showing clearance of antigen expressing hepatocytes by CD8+ T cells. PLoS ONE 8, e68720 (2013).
pubmed: 23869228 pmcid: 3711822 doi: 10.1371/journal.pone.0068720
Cheung, A. F., Dupage, M. J., Dong, H. K., Chen, J. & Jacks, T. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res. 68, 9459–9468 (2008).
pubmed: 19010921 pmcid: 2597052 doi: 10.1158/0008-5472.CAN-08-2634
Strandt, H. et al. Neoantigen expression in steady-state langerhans cells induces CTL tolerance. J. Immunol. 199, 1626–1634 (2017).
pubmed: 28739880 pmcid: 5563165 doi: 10.4049/jimmunol.1602098
Brockschnieder, D., Pechmann, Y., Sonnenberg-Riethmacher, E. & Riethmacher, D. An improved mouse line for Cre-induced cell ablation due to diphtheria toxin A, expressed from the Rosa26 locus. Genesis 44, 322–327 (2006).
pubmed: 16791847 doi: 10.1002/dvg.20218
Lee, P. et al. Conditional lineage ablation to model human diseases. Proc. Natl Acad. Sci. USA 95, 11371–11376 (1998).
pubmed: 9736743 doi: 10.1073/pnas.95.19.11371
Malhotra, D. et al. Tolerance is established in polyclonal CD4(+) T cells by distinct mechanisms, according to self-peptide expression patterns. Nat. Immunol. 17, 187–195 (2016).
pubmed: 26726812 pmcid: 4718891 doi: 10.1038/ni.3327
Probst, H. C., Lagnel, J., Kollias, G. & van den Broek, M. Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity 18, 713–720 (2003).
pubmed: 12753747 doi: 10.1016/S1074-7613(03)00120-1
Esterhazy, D. et al. Compartmentalized gut lymph node drainage dictates adaptive immune responses. Nature 569, 126–130 (2019).
pubmed: 30988509 pmcid: 6587593 doi: 10.1038/s41586-019-1125-3
Luo, X. et al. ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. Proc. Natl Acad. Sci. USA 105, 14527–14532 (2008).
pubmed: 18796615 doi: 10.1073/pnas.0805204105
Kontos, S., Kourtis, I. C., Dane, K. Y. & Hubbell, J. A. Engineering antigens for in situ erythrocyte binding induces T-cell deletion. Proc. Natl Acad. Sci. USA 110, E60–E68 (2013).
pubmed: 23248266 doi: 10.1073/pnas.1216353110
Hlavaty, K. A. et al. Tolerance induction using nanoparticles bearing HY peptides in bone marrow transplantation. Biomaterials 76, 1–10 (2016).
pubmed: 26513216 doi: 10.1016/j.biomaterials.2015.10.041
Lutterotti, A. et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci. Transl. Med. 5, 188ra175 (2013).
doi: 10.1126/scitranslmed.3006168
Wilson, D. S. et al. Synthetically glycosylated antigens induce antigen-specific tolerance and prevent the onset of diabetes. Nat. Biomed. Eng. 3, 817–829 (2019).
pubmed: 31358881 doi: 10.1038/s41551-019-0424-1
Hogquist, K. A., Baldwin, T. A. & Jameson, S. C. Central tolerance: learning self-control in the thymus. Nat. Rev. Immunol. 5, 772–782 (2005).
pubmed: 16200080 doi: 10.1038/nri1707
Anderson, M. S. et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 298, 1395–1401 (2002).
doi: 10.1126/science.1075958 pubmed: 12376594
Klein, L., Roettinger, B. & Kyewski, B. Sampling of complementing self-antigen pools by thymic stromal cells maximizes the scope of central T cell tolerance. Eur. J. Immunol. 31, 2476–2486 (2001).
pubmed: 11500832 doi: 10.1002/1521-4141(200108)31:8<2476::AID-IMMU2476>3.0.CO;2-T pmcid: 11500832
McGargill, M. A., Derbinski, J. M. & Hogquist, K. A. Receptor editing in developing T cells. Nat. Immunol. 1, 336–341 (2000).
pubmed: 11017106 doi: 10.1038/79790 pmcid: 11017106
Ohashi, P. S. et al. Ablation of ‘tolerance’ and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65, 305–317 (1991).
pubmed: 1901764 doi: 10.1016/0092-8674(91)90164-T pmcid: 1901764
Zehn, D. & Bevan, M. J. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 25, 261–270 (2006).
pubmed: 16879996 pmcid: 2774714 doi: 10.1016/j.immuni.2006.06.009
Kisielow, P., Bluthmann, H., Staerz, U. D., Steinmetz, M. & von Boehmer, H. Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4
doi: 10.1038/333742a0 pubmed: 3260350
Sha, W. C. et al. Positive and negative selection of an antigen receptor on T cells in transgenic mice. Nature 336, 73–76 (1988).
pubmed: 3263574 doi: 10.1038/336073a0
Miller, J. F. & Flavell, R. A. T-cell tolerance and autoimmunity in transgenic models of central and peripheral tolerance. Curr. Opin. Immunol. 6, 892–899 (1994).
pubmed: 7710713 doi: 10.1016/0952-7915(94)90010-8
Agudo, J. et al. GFP-specific CD8 T cells enable targeted cell depletion and visualization of T-cell interactions. Nat. Biotechnol. 33, 1287–1292 (2015).
pubmed: 26524661 pmcid: 4675673 doi: 10.1038/nbt.3386
Schlake, T. & Bode, J. Use of mutated FLP recognition target (FRT) sites for the exchange of expression cassettes at defined chromosomal loci. Biochemistry 33, 12746–12751 (1994).
pubmed: 7947678 doi: 10.1021/bi00209a003
Raymond, C. S. & Soriano, P. ROSA26Flpo deleter mice promote efficient inversion of conditional gene traps in vivo. Genesis 48, 603–606 (2010).
pubmed: 20665730 pmcid: 2958239 doi: 10.1002/dvg.20659
Schnutgen, F. et al. Enhanced gene trapping in mouse embryonic stem cells. Nucleic Acids Res. 36, e133 (2008).
pubmed: 18812397 pmcid: 2582619 doi: 10.1093/nar/gkn603
Homann, D. et al. Mapping and restriction of a dominant viral CD4+ T cell core epitope by both MHC class I and MHC class II. Virology 363, 113–123 (2007).
pubmed: 17320138 pmcid: 1976554 doi: 10.1016/j.virol.2006.12.025
Mannering, S. I. et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J. Exp. Med. 202, 1191–1197 (2005).
pubmed: 16260488 pmcid: 2213236 doi: 10.1084/jem.20051251
Skowera, A. et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J. Clin. Invest. 118, 3390–3402 (2008).
pubmed: 18802479 pmcid: 2542849
Dunne, J. L., Overbergh, L., Purcell, A. W. & Mathieu, C. Posttranslational modifications of proteins in type 1 diabetes: the next step in finding the cure? Diabetes 61, 1907–1914 (2012).
pubmed: 22826307 pmcid: 3402302 doi: 10.2337/db11-1675
Carrillo-Vico, A., Leech, M. D. & Anderton, S. M. Contribution of myelin autoantigen citrullination to T cell autoaggression in the central nervous system. J. Immunol. 184, 2839–2846 (2010).
pubmed: 20164413 doi: 10.4049/jimmunol.0903639
Dorum, S. et al. The preferred substrates for transglutaminase 2 in a complex wheat gluten digest are peptide fragments harboring celiac disease T-cell epitopes. PLoS ONE 5, e14056 (2010).
pubmed: 21124911 pmcid: 2988817 doi: 10.1371/journal.pone.0014056
Grunewald, J. et al. Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids. Proc. Natl Acad. Sci. USA 106, 4337–4342 (2009).
pubmed: 19246393 doi: 10.1073/pnas.0900507106
Myers, L. K. et al. Relevance of posttranslational modifications for the arthritogenicity of type II collagen. J. Immunol. 172, 2970–2975 (2004).
pubmed: 14978100 doi: 10.4049/jimmunol.172.5.2970
Joshi, N. S. et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 43, 579–590 (2015).
pubmed: 26341400 pmcid: 4826619 doi: 10.1016/j.immuni.2015.08.006
Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243–3248 (2001).
pubmed: 11751630 pmcid: 312845 doi: 10.1101/gad.943001
DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064–1072 (2009).
pubmed: 19561589 pmcid: 2757265 doi: 10.1038/nprot.2009.95
Luche, H., Weber, O., Nageswara Rao, T., Blum, C. & Fehling, H. J. Faithful activation of an extra-bright red fluorescent protein in ‘knock-in’ Cre-reporter mice ideally suited for lineage tracing studies. Eur. J. Immunol. 37, 43–53 (2007).
pubmed: 17171761 doi: 10.1002/eji.200636745 pmcid: 17171761
Nielsen, M. et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12, 1007–1017 (2003).
pubmed: 12717023 pmcid: 2323871 doi: 10.1110/ps.0239403
Andreatta, M. & Nielsen, M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 32, 511–517 (2016).
pubmed: 26515819 doi: 10.1093/bioinformatics/btv639 pmcid: 26515819

Auteurs

Martina Damo (M)

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.

Brittany Fitzgerald (B)

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.

Yisi Lu (Y)

Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.

Mursal Nader (M)

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.

Ivana William (I)

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.

Julie F Cheung (JF)

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.

Kelli A Connolly (KA)

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.

Gena G Foster (GG)

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.

Elliot Akama-Garren (E)

Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.

Da-Yae Lee (DY)

Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.

Greg P Chang (GP)

Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.

Vasilena Gocheva (V)

Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.

Leah M Schmidt (LM)

Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.

Alice Boileve (A)

Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.

Josephine H Wilson (JH)

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.

Can Cui (C)

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.

Isabel Monroy (I)

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.

Prashanth Gokare (P)

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.

Peter Cabeceiras (P)

Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.

Tyler Jacks (T)

Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. tjacks@mit.edu.
Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA, USA. tjacks@mit.edu.

Nikhil S Joshi (NS)

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA. nikhil.joshi@yale.edu.
Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. nikhil.joshi@yale.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH